SCHEMBL2669643

SCHEMBL2669643

COCCOc1ccc(Nc2ccn(C)n2)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.40
SRC P12931 2/20 0.39
BTK Q06187 2/20 0.39
HPGDS O60760 1/20 0.39
CCNE1 P24864 4/20 0.39
CDK2 P24941 4/20 0.39
HSF1 Q00613 3/20 0.39
CCNT1 O60563 2/20 0.39
CDK9 P50750 2/20 0.39
MAPK1 P28482 1/20 0.38
PIK3CA P42336 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
GCK P35557 4/20 0.36
IGF1R P08069 2/20 0.36
LRRK2 Q5S007 1/20 0.36
SYK P43405 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657982 0.88 CYP19A1 (0.47) CYP19A1SRCBTKCCNE1CDK2
SCHEMBL2657070 0.84 HPGDS (0.45) SRCBTKHPGDSMAPK1PIK3CA
SCHEMBL2657999 0.81 MAPK1 (0.38) SRCBTKMAPK1PIK3CAMAPK8
SCHEMBL2658986 0.79 P4HTM (0.44) BTKGCK
SCHEMBL23768090 0.75 APP (0.40)
SCHEMBL2656963 0.74 CCNE1 (0.42) CCNE1CDK2HSF1GCKIGF1R
SCHEMBL14839422 0.72 ALDH1A1 (0.41) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL15688182 0.72 LRRK2 (0.44) SRCBTKMAPK1PIK3CAMAPK8
SCHEMBL2658963 0.72 HCK (0.42) BTKGCK
SCHEMBL2669499 0.72 GCK (0.49) MAPK1PIK3CAMAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420642-B2 Pyridine derivatives useful as glucokinase activators MERCK PATENT GMBH (DE) 2013-04-16 US disclosed
US-8420642-B2 Pyridine derivatives useful as glucokinase activators MERCK PATENT GMBH (DE) 2013-04-16 US disclosed
US-20100216794-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-08-26 US disclosed
US-20100216794-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-08-26 US disclosed
WO-2009046784-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216794-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS HK1, GCKR, GCK CYP19A1 1094/4885SRC 3104/4885BTK 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.